Elicio - Model ELI-007 - Multivalent Lymph Node–Targeted AMP Peptide Vaccine

ELI-007 is a multivalent lymph node–targeted AMP peptide vaccine developed to target BRAF gene mutations. The BRAF gene is part of an intracellular signaling pathway that drives cell growth and division.¹ BRAF mutations can lead to uncontrolled cell growth and ultimately cancer. BRAF mutations are present in multiple types of cancer, including 40% in melanoma, 9% in colorectal cancer (CRC), and 2% in lung cancer. High levels of BRAF protein expression in these tumors suggest susceptibility to T cells targeting the mutation.³ Previous research has shown a durable complete response through transfer of tumor-infiltrating lymphocytes recognizing mutated BRAF.³ By harnessing the ability to train T cells to target specific antigens, ELI-007 has the potential to generate tumor-specific immunity capable of eliminating BRAF-driven cancers.